Biotech Values

[vinmantoo]

iwfal

<PPS I also note that I see no reason, in the above example, to believe that these kinds of effects (slow-one-subtype, speed-another-subtype) should be limited to just direct kinase inhibitors. Anything that acts on a kinase pathway (e.g. HSP90 inhibitors) could, in theory, do the same thing since it appears to be inherent in the complex control loop interaction of the kinases.>

One can't disagree with your comment as a general point. However one can easily make the point that high specificity of a treatment could be a negative rather than the Holy Grail it as been touted to be. I believe someone has already made this point on board regarding kinase inhibitors. I will venture that HSP90 inhibitors will have that same benefit of lack of specificity as they modulate a large variety of proteins.